Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric D Hsi

Showing results (131-140 of 330) with videos related to

Pageof 33
Sort By:
Blood|April 15, 2006
Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndromeMarcin W Wlodarski, Lukasz P Gondek, Zachary P Nearman, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|June 5, 2002
Diffuse large B-cell lymphoma of the stomach: assessment of microsatellite instability, allelic imbalance, and trisomy of chromosomes 3, 12, and 18Marek Skacel, Pamela L Paris, James D Pettay, et al.
American Journal of Clinical Pathology|May 19, 2006
MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosisEric D Hsi, Stephen J Sup, Carlos Alemany, et al.
Cell Death & Disease|December 6, 2019
Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignanciesIsha Kapoor, Yue Li, Arishya Sharma, et al.
American Journal of Clinical Pathology|April 10, 2002
Primary cutaneous diffuse large B-cell lymphoma: a clinicopathologic study of 15 casesThomas A Hembury, Benita Lee, Randy D Gascoyne, et al.
British Journal of Haematology|July 30, 2013
The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathwaysJuraj Bodo, Xiaoxian Zhao, Arishya Sharma, et al.
Blood|June 3, 2006
Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutationHadrian Szpurka, Ramon Tiu, Gurunathan Murugesan, et al.
Leukemia Research|March 26, 2010
Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutationsHadrian Szpurka, Anna M Jankowska, Hideki Makishima, et al.
Histopathology|October 15, 2024
Closing the gap between biology and classification in splenic B-cell lymphomasPiers Blombery, Daphne de Jong, Judith A Ferry, et al.
American Journal of Clinical Pathology|August 3, 2025
An immunohistochemical germinal center B-cell dark zone signature identifies Burkitt lymphoma and molecular high-grade B-cell lymphomasXiaoxian Zhao, Alexandra Balmaceda, Via S Abiera, et al.
Pageof 33

Showing results (131-140 of 330) with videos related to

Sort By:
Pageof 33
Blood|April 15, 2006
Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndromeMarcin W Wlodarski, Lukasz P Gondek, Zachary P Nearman, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|June 5, 2002
Diffuse large B-cell lymphoma of the stomach: assessment of microsatellite instability, allelic imbalance, and trisomy of chromosomes 3, 12, and 18Marek Skacel, Pamela L Paris, James D Pettay, et al.
American Journal of Clinical Pathology|May 19, 2006
MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosisEric D Hsi, Stephen J Sup, Carlos Alemany, et al.
Cell Death & Disease|December 6, 2019
Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignanciesIsha Kapoor, Yue Li, Arishya Sharma, et al.
American Journal of Clinical Pathology|April 10, 2002
Primary cutaneous diffuse large B-cell lymphoma: a clinicopathologic study of 15 casesThomas A Hembury, Benita Lee, Randy D Gascoyne, et al.
British Journal of Haematology|July 30, 2013
The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathwaysJuraj Bodo, Xiaoxian Zhao, Arishya Sharma, et al.
Blood|June 3, 2006
Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutationHadrian Szpurka, Ramon Tiu, Gurunathan Murugesan, et al.
Leukemia Research|March 26, 2010
Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutationsHadrian Szpurka, Anna M Jankowska, Hideki Makishima, et al.
Histopathology|October 15, 2024
Closing the gap between biology and classification in splenic B-cell lymphomasPiers Blombery, Daphne de Jong, Judith A Ferry, et al.
American Journal of Clinical Pathology|August 3, 2025
An immunohistochemical germinal center B-cell dark zone signature identifies Burkitt lymphoma and molecular high-grade B-cell lymphomasXiaoxian Zhao, Alexandra Balmaceda, Via S Abiera, et al.
Pageof 33